ATE424194T1 - Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson - Google Patents

Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Info

Publication number
ATE424194T1
ATE424194T1 AT02759761T AT02759761T ATE424194T1 AT E424194 T1 ATE424194 T1 AT E424194T1 AT 02759761 T AT02759761 T AT 02759761T AT 02759761 T AT02759761 T AT 02759761T AT E424194 T1 ATE424194 T1 AT E424194T1
Authority
AT
Austria
Prior art keywords
adenosine
parkinson
disease
treatment
compounds
Prior art date
Application number
AT02759761T
Other languages
English (en)
Inventor
Dan Peters
Lars Christian Roenn
Karin Sandager Nielsen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE424194T1 publication Critical patent/ATE424194T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AT02759761T 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson ATE424194T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100583 2001-04-09

Publications (1)

Publication Number Publication Date
ATE424194T1 true ATE424194T1 (de) 2009-03-15

Family

ID=8160425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759761T ATE424194T1 (de) 2001-04-09 2002-04-04 Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Country Status (8)

Country Link
US (1) US7160899B2 (de)
EP (1) EP1379269B1 (de)
JP (1) JP2004529916A (de)
AT (1) ATE424194T1 (de)
CA (1) CA2440196A1 (de)
DE (1) DE60231386D1 (de)
MX (1) MXPA03009185A (de)
WO (1) WO2002080957A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420636T1 (de) * 1999-05-19 2009-01-15 Painceptor Pharma Corp Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
JP2004523543A (ja) * 2001-02-15 2004-08-05 ニューロサーチ、アクティーゼルスカブ 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法
BR0306919A (pt) * 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
TWI331036B (en) 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl) * 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
US20090246134A1 (en) * 2007-05-30 2009-10-01 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
HRP20251187T1 (hr) 2013-07-12 2025-11-21 Areteia Therapeutics, Inc. Liječenje povišenih razina eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
WO2018170359A1 (en) * 2017-03-17 2018-09-20 University Of Virginia Patent Foundation Compositions and methods for treating peripheral nerve disease, disorders, and injuries
CN114901665B (zh) * 2019-12-26 2025-02-18 浙江春禾医药科技有限公司 三唑并三嗪衍生物在治疗疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
US5574060A (en) 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
FR2734264B1 (fr) 1995-05-19 1997-08-01 Lafon Labor Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
JP3462505B2 (ja) 1995-10-13 2003-11-05 ノイロサーチ アクティーゼルスカブ ８−アザビシクロ［３．２．１］オクト−２−エン誘導体、それらの製造及び使用
RU2162469C2 (ru) 1995-11-02 2001-01-27 Ньюросерч А/С Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
WO1998006689A1 (en) 1996-08-16 1998-02-19 Allelix Pharm-Eco, L.L.P. Slow-onset, long-lasting dopamine reuptake blockers
US5821386A (en) 1997-08-15 1998-10-13 Allelix-Pharm-Eco L.P. Compounds for treating cocaine abuse
US6001330A (en) 1997-09-12 1999-12-14 Elmaleh; David R. Diagnostic and therapeutic alkylenediamine compounds and process
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
CA2329624A1 (en) * 1998-04-23 1999-10-28 Koki Kato Pharmaceutical composition for neurotrophic action
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
AU2001259252A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Neuroprotective compositions

Also Published As

Publication number Publication date
US7160899B2 (en) 2007-01-09
CA2440196A1 (en) 2002-10-17
DE60231386D1 (de) 2009-04-16
US20040097540A1 (en) 2004-05-20
EP1379269A1 (de) 2004-01-14
EP1379269B1 (de) 2009-03-04
WO2002080957A1 (en) 2002-10-17
JP2004529916A (ja) 2004-09-30
MXPA03009185A (es) 2004-02-17

Similar Documents

Publication Publication Date Title
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
NZ522326A (en) Adenosine A2A receptor antagonists
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
TR200200408T2 (tr) Yeni spiro bileşikleri
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
PA8521501A1 (es) Ligandos para receptores de melanocortina
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
EA200400399A1 (ru) Способы лечения легочных заболеваний
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0000486A (pt) Antagonistas do neuropeptìdeo y

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties